Anne B. Young | Academic Influence

Anne B. Young's AcademicInfluence.com Rankings

Anne B. Young

Biology

#2913

World Rank

#4543

Historical Rank

#1248

USA Rank

Neuroscience

#269

World Rank

#284

Historical Rank

#104

USA Rank

biology Degrees

Download Badge

Biology

Anne B. Young's Degrees

Doctorate Medicine Harvard University

Why Is Anne B. Young Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Anne Buckingham Young is an American physician and neuroscientist who has made major contributions to the study of neurodegenerative diseases, with a focus on movement disorders like Huntington's disease and Parkinson's disease. Young completed her undergraduate studies at Vassar College and earned a dual MD/PhD from Johns Hopkins Medical School. She has held faculty positions at University of Michigan and Harvard University. She became the first female chief of service at Massachusetts General Hospital when she was appointed Chief of Neurology in 1991. She retired from this role and from clinical service in 2012. She is a member of many academic societies and has won numerous awards. Young is also the only person to have been president of both the international Society for Neuroscience and the American Neurological Association.

(See a Problem?)

Anne B. Young's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The functional anatomy of basal ganglia disorders (1989) (5064)
Differential loss of striatal projection neurons in Huntington disease. (1988) (982)
Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease (2007) (881)
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. (2000) (758)
Regional and cellular gene expression changes in human Huntington's disease brain. (2006) (746)
Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease (2002) (700)
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease (2010) (699)
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease (1999) (642)
Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. (1998) (527)
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. (2007) (526)
Excitatory amino acids and Alzheimer's disease (1989) (489)
Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system (1989) (440)
Speculations on the functional anatomy of basal ganglia disorders. (1983) (432)
NMDA receptor losses in putamen from patients with Huntington's disease. (1988) (408)
Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. (1990) (397)
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. (2002) (387)
Organization of N‐methyl‐D‐aspartate glutamate receptor gene expression in the basal ganglia of the rat (1994) (379)
Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. (1985) (375)
Homozygotes for Huntington's disease (1987) (372)
Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study (1992) (372)
Strychnine binding associated with glycine receptors of the central nervous system. (1973) (367)
Distribution and kinetics of GABAB binding sites in rat central nervous system: A quantitative autoradiographic study (1990) (366)
Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease (1992) (354)
Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system (1984) (353)
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases. (1985) (348)
The functional anatomy of disorders of the basal ganglia (1995) (347)
Glutamate dysfunction in Alzheimer's disease: an hypothesis (1987) (342)
Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. (1974) (336)
Striatal inhomogeneities and basal ganglia function (1986) (333)
PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline (1986) (297)
Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding (1987) (294)
Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia (1990) (285)
Comparative distribution of dopamine D‐1 and D‐2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys (1987) (273)
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. (2005) (269)
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. (2006) (267)
Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. (1990) (265)
Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. (1987) (251)
Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. (1999) (249)
GABA as the pallidothalamic neurotransmitter: implications for basal ganglia function (1981) (240)
Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals (1990) (231)
Metabotropic glutamate receptors are differentially regulated during development (1994) (231)
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. (2002) (224)
Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals (1995) (222)
Clinical trials in head injury. (1999) (211)
Treatment for patients with cerebral metastases. (1978) (210)
Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. (2002) (204)
Tetanus toxin: direct evidence for retrograde intraaxonal transport. (1975) (203)
Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study (2004) (200)
In vivo cerebral metabolism and central benzodiazepine‐receptor binding in temporal lobe epilepsy (1993) (194)
Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons (1995) (190)
Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. (1997) (188)
Expression of Normal and Mutant Huntingtin in the Developing Brain (1996) (187)
Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice (2003) (185)
Differential ontogenic development of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus (1990) (180)
Initial therapy of patients with Wilson's disease with tetrathiomolybdate. (1991) (178)
Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography (1983) (178)
Glutamate transmission and toxicity in alzheimer's disease (1988) (177)
CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain (1995) (177)
Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. (1996) (177)
Strychnine Binding in Rat Spinal Cord Membranes Associated with the Synaptic Glycine Receptor: Cooperativity of Glycine Interactions (1974) (176)
Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. (1999) (175)
Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis (1995) (168)
Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function (1988) (167)
Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia (1999) (164)
PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site (1989) (163)
Huntington's disease in Venezuela (1986) (161)
γ‐Aminobutyric Acid and Benzodiazepine Receptor Changes Induced by Unilateral 6‐Hydroxydopamine Lesions of the Medial Forebrain Bundle (1985) (158)
Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia (2005) (154)
Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. (2002) (152)
Intolerance to enteral feeding in the brain-injured patient. (1988) (149)
Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes. (1988) (146)
Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. (1999) (144)
3‐Nitropropionic Acid Toxicity in the Striatum (1994) (144)
Decreased glutamate uptake in subcortical areas deafferented by sensorimotor cortical ablation in the cat (1981) (142)
Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice (2005) (140)
The acute-phase response of the brain-injured patient. (1988) (134)
Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat. (1994) (132)
The glycine synaptic receptor: evidence that strychnine binding is associated with the ionic conductance mechanism. (1974) (130)
Imaging of a glioma using peripheral benzodiazepine receptor ligands. (1987) (127)
Interaction of benzodiazepines with central nervous glycine receptors: possible mechanism of action. (1974) (125)
Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex (1998) (124)
Age-related changes in the protein expression of subunits of the NMDA receptor. (2002) (123)
Huntingtin in health and disease. (2003) (123)
High correlation between the localization of [3H]TCP binding and NMDA receptors. (1986) (122)
Quantitative autoradiography of [3H]muscimol binding in rat brain. (1981) (122)
At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. (1987) (122)
Quantitative autoradiography of neurotransmitter receptors in Huntington disease (1982) (119)
Comparative distributions of dopamine D‐1 and D‐2 receptors in the cerebral cortex of rats, cats, and monkeys (1989) (118)
Wilson disease of the brain: MR imaging. (1985) (117)
Evaluation of traumatic atlantooccipital dislocations. (1987) (117)
Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain (1991) (115)
A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse (2007) (114)
Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat (1992) (113)
Expression of the early‐onset torsion dystonia gene (DYT1) in human brain (1998) (113)
Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum (2000) (111)
Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation (2003) (109)
Autoradiographic Characterization and Localization of Quisqualate Binding Sites in Rat Brain Using the Antagonist [3H]6‐Cyano‐7‐Nitroquinoxaline‐2,3‐Dione: Comparison with (R,S)‐[3H]α‐Amino‐3‐Hydroxy‐5‐Methyl‐4‐Isoxazolepropionic Acid Binding Sites (1990) (107)
Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. (1990) (107)
Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity (1989) (107)
Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. (2005) (104)
Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. (2005) (103)
Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 (1995) (103)
Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions (1994) (103)
Synaptic localization of striatal NMDA, quisqualate and kainate receptors (1989) (95)
Synaptic biochemistry of amino acids. (1973) (94)
Distribution of GABAA and GABAB receptors in mammalian brain: Potential targets for drug development (1990) (93)
Loss of hippocampal [3H]TCP binding in Alzheimer's disease (1987) (92)
Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of huntington's disease (1991) (91)
Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. (2000) (91)
Myopathy as a first symptom of Huntington's disease in a Marathon runner (2007) (91)
Cortical GABAB and GABAA receptors in Alzheimer's disease (1987) (90)
Regionally Distinct N‐Methyl‐D‐Aspartate Receptors Distinguished by Quantitative Autoradiography of [3H]MK‐801 Binding in Rat Brain (1993) (88)
Normal caudate glucose metabolism in persons at risk for Huntington's disease. (1987) (84)
Autoradiographic localization of cerebellar excitatory amino acid binding sites in the mouse (1987) (82)
Benzodiazepine and GABA receptors in early Huntington's disease (1984) (82)
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS (2013) (82)
Glutamate receptors in the substantia nigra of Parkinson's disease brains (1992) (82)
l-[3H]Glutamate labels the metabotropic excitatory amino acid receptor in rodent brain (1990) (80)
Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers (1984) (77)
Positron emission tomography measures of benzodiazepine receptors in Huntington's disease (1993) (76)
Interrater agreement in the assessment of motor manifestations of Huntington's disease (2005) (76)
Compartmentalization of excitatory amino acid receptors in human striatum. (1992) (74)
Excitatory amino acid binding sites in the periaqueductal gray of the rat (1990) (73)
Glutamate or aspartate as a possible neurotransmitter of cerebral corticofugal fibers in the monkey (1983) (73)
GABA and bicuculline actions on mouse spinal cord and cortical neurons in cell culture (1982) (72)
Milestones in Huntington disease (2011) (72)
Preproenkephalin messenger RNA—containing neurons in striatum of patients with symptomatic and presymptomatic huntington's disease: An in situ hybridization study (1991) (72)
Characterization and regional distribution of strychnine-insensitive [3H]glycine binding sites in rat brain by quantitative receptor autoradiography (1990) (71)
High protein enteral feedings: a means of achieving positive nitrogen balance in head injured patients. (1985) (70)
Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer's disease (1987) (70)
Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. (2003) (68)
Huntingtin Immunoreactivity in the Rat Neostriatum: Differential Accumulation in Projection and Interneurons (1997) (68)
Glutamate receptor expression in rat striatum: Effect of deafferentation (1994) (68)
Alternatively spliced isoforms of the NMDAR1 glutamate receptor subunit: Differential expression in the basal ganglia of the rat (1993) (67)
Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy (2009) (67)
The globus pallidus receives a projection from the parafascicular nucleus in the rat (1991) (67)
Thiocyanate stabilizes AMPA binding to the quisqualate receptor. (1988) (66)
Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus (1998) (66)
Gamma Knife surgery for the management of glomus tumors: a multicenter study. (2012) (65)
Evidence for a projection from the globus pallidus to the entopeduncular nucleus in the rat (1991) (64)
Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. (1999) (63)
The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity (2001) (63)
Evidence for glutamate as the neurotransmitter of corticothalamic and corticorubral pathways (1981) (63)
Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. (2003) (62)
Mechanisms and implications of hypoalbuminemia in head-injured patients. (1988) (62)
Quisqualate‐ and NMDA‐sensitive [3H]glutamate binding in primate brain (1990) (58)
NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex (1993) (58)
Properties of D2 dopamine receptor autoradiography: High percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections (1986) (57)
Changes in the expression of the NR2B subunit during aging in macaque monkeys (2004) (57)
Properties of Quisqualate‐Sensitive L‐[3H]Glutamate Binding Sites in Rat Brain as Determined by Quantitative Autoradiography (1988) (57)
6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamate decarboxylase messenger RNA in rat globus pallidus projection neurons (1992) (57)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat (1998) (54)
Glycine-specific synapses in rat spinal cord. Identification by electron microscope autoradiography (1976) (53)
Four Decades of Neurodegenerative Disease Research: How Far We Have Come! (2009) (52)
Cloning and stable expression of the mGluR1b subtype of human metabotropic receptors and pharmacological comparison with the mGluR5a subtype (1997) (52)
New form of familial Parkinson‐dementia syndrome (1983) (50)
Expression of N-methyl- d-aspartate glutamate receptor subunits in the prefrontal cortex of the rat (1996) (50)
Isoquinoline and peripheral-type benzodiazepine binding in gliomas: implications for diagnostic imaging. (1988) (49)
Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. (2002) (49)
Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brain (1997) (49)
Brain mechanisms associated with therapeutic actions of benzodiazepines: focus on neurotransmitters. (1977) (48)
Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions (1995) (48)
Quantitative autoradiography of L-[3H]glutamate binding to rat brain (1983) (46)
Metabotropic glutamate receptor heterogeneity in rat brain. (1994) (45)
Neurochemical anatomy of movement disorders. (1984) (45)
Metastatic spinal cord compression: a randomized trial of direct decompressive surgical resection plus radiotherapy vs. radiotherapy alone (2003) (44)
Phosphorylation of the homer‐binding domain of group I metabotropic glutamate receptors by cyclin‐dependent kinase 5 (2009) (43)
Glutamate Receptor Dysregulation in the Hippocampus of Transgenic Mice Carrying Mutated Human Amyloid Precursor Protein (2001) (43)
Neuropathology in Tourette syndrome: an update. (2001) (43)
Expression of N‐Methyl‐D‐Aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons (1998) (42)
The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. (2000) (41)
What's the excitement about excitatory amino acids in amyotrophic lateral sclerosis? (1990) (40)
N-Acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo (1997) (39)
Quantitative autoradiographic localization of NMDA, quisqualate and PCP receptors in the frog tectum (1989) (39)
Nuclear Localization of Histamine in Neonatal Rat Brain (1971) (39)
Phospholipase A2 Modulates Different Subtypes of Excitatory Amino Acid Receptors: Autoradiographic Evidence (1993) (38)
Phenytoin-dexamethasone interaction: a previously unreported observation. (1981) (38)
Synthesis of a high specific activity 125I-labeled analog of PK 11195, potential agent for SPECT imaging of the peripheral benzodiazepine binding site. (1989) (36)
GABA binding and bicuculline in spinal cord and cortical membranes from adult rat and from mouse neurons in cell culture (1982) (36)
Tetrahydro-9-aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site (1988) (35)
Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neurons (2002) (35)
Sodium-dependentd-aspartate ‘binding’ is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay (1990) (35)
Development of the synaptic glycine receptor in chick embryo spinal cord (1975) (34)
Anatomical Distribution of Metabotropic Glutamate Receptors in Mammalian Brain (1994) (33)
Basal ganglia and cerebral cortical distribution of dopamine D1- and D2-receptors in neonatal and adult cat brain (1987) (33)
Excitatory amino acid receptor regulation after subthalamic nucleus lesions in the rat (1993) (33)
Recursive Partitioning Analysis Classifications I and II: Applicability Evaluated in a Randomized Trial for Resected Single Brain Metastases (2004) (32)
Quantitative autoradiography of neurotransmitter receptors using tritium-sensitive film. (1981) (32)
Aplasia of the cervical internal carotid artery and malformation of the circle of Willis associated with Klippel-Trenaunay syndrome. Case report. (1984) (32)
Multiple states of rat brain (RS)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors as revealed by quantitative autoradiography. (1992) (32)
Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probes. (1998) (31)
Cellular Distribution of NMDA Glutamate Receptor Subunit mRNAs in the Human Cerebellum (1997) (30)
2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces [3H]AMPA binding in rat striatum (1991) (29)
Occipital condyle fracture associated with cervical spine injury. (1982) (29)
Localization of non–N‐methyl‐D‐aspartate glutamate receptors in normal and Alzheimer hippocampal formation (1994) (29)
Regional ontogeny of a unique glutamate recognition site in rat brain: An autoradiographic study (1990) (28)
Quisqualate resolves two distinct metabotropic [3H]glutamate binding sites. (1993) (27)
Myoclonus in adult Huntington's disease (1991) (27)
Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography. (1988) (27)
Native Mutant Huntingtin in Human Brain (2012) (27)
Glutamate Receptor Binding Sites in MPTP-Treated Mice (1993) (26)
Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. (1999) (26)
Treatment of Wilson's disease. (1987) (26)
Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments (2007) (25)
Ultrastructure of pineal parenchymal neoplasms (2004) (25)
Differential localization of the mRNAs for the pertussis toxin insensitive G-protein alpha sub-units Gq, G11, and Gz in the rat brain, and regulation of their expression after striatal deafferentation. (1998) (25)
Magnetic resonance features of the enigmatic oligodendroglioma. (1998) (25)
NMDA receptor channels: labeling of MK-801 with iodine-125 and fluorine-18. (1988) (25)
Huntington's disease in Venezuela: Neurologic features and functional decline (2011) (24)
Radioiodinated benzodiazepines: agents for mapping glial tumors. (1988) (24)
Effects of verapamil and diltiazem on acute stroke in cats. (1985) (24)
Characterization of benzodiazepine receptor changes in substantia nigra, globus pallidus and entopeduncular nucleus after striatal lesions. (1984) (24)
Decreased Lin7b Expression in Layer 5 Pyramidal Neurons May Contribute to Impaired Corticostriatal Connectivity in Huntington Disease (2010) (23)
Muscarinic cholinergic receptors in human infant forebrain: [3H]quinuclidinyl benzilate binding in homogenates and quantitative autoradiography in sections. (1985) (23)
IT15 gene expression in fetal human brain (1994) (23)
Cortical amino acidergic pathways in Alzheimer's disease. (1987) (23)
Excitatory amino acid, GABA(A), and GABA(B) binding sites in human striate cortex. (1991) (22)
Somatosensory phenomena in Huntington's disease (1988) (22)
Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat. (1993) (22)
DNA Fragmentation and Immediate Early Gene Expression in Rat Striatum Following Quinolinic Acid Administration (1995) (21)
Neutron interstitial brachytherapy for malignant gliomas: a pilot study. (1988) (21)
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease (2016) (21)
Neuropathology in Tourette Syndrome (1999) (20)
Comparison of [14C]‐deoxyglucose metabolism and peripheral benzodiazepine receptor binding in rat C6 glioma (1988) (20)
Cerebellar excitatory amino acid binding sites in normal, granuloprival, and purkinje cell-deficient mice (1991) (20)
Preliminary report of a phase I study of combined fractionated stereotactic radiosurgery and conventional external beam radiation therapy for unfavorable gliomas. (2000) (19)
Craniopharyngioma intrinsic to the third ventricle. (1983) (19)
Role of excitotoxins in heredito-degenerative neurological diseases (1991) (19)
Effects of chronic denervation on the histology of canine extraocular muscle. (1982) (18)
Two types of quisqualate receptors are decreased in human olivopontocerebellar atrophy cerebellar cortex (1990) (18)
Autoradiographic evidence for increased dopamine uptake sites in striatum of hypoxic mice (1994) (17)
Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. (1981) (17)
Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. (1991) (17)
Thromboxane synthetase inhibition with imidazole increases blood flow in ischemic penumbra. (1988) (16)
A study of cortical and hippocampal NMDA and PCP receptors following selective cortical and subcortical lesions (1991) (16)
Work in progress: 252Cf neutron brachytherapy for hemispheric malignant glioma. (1982) (15)
Comparison of Administration of Two Standard Intravenous Amino Acid Formulas to Severely Brain-Injured Patients (1988) (15)
Percutaneous radiofrequency sacral rhizotomy in the treatment of the hyperreflexic bladder. (1978) (14)
Levodopa-Induced Dyskinesia Is Associated with Increased Thyrotropin Releasing Hormone in the Dorsal Striatum of Hemi-Parkinsonian Rats (2010) (14)
Metabotropic glutamate receptor 1 (mGluR1): Antibody specificity and receptor expression in cultured primary neurons (2012) (14)
Cerebellar excitatory and inhibitory amino acid receptors in multiple system atrophy (1993) (13)
Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease. (2016) (13)
Glutamic Acid, a Putative Neurotransmitter of Cerebellar Granule Cells: Evidence from the Virally Induced Granuloprival Cerebellum (1975) (13)
Chapter 2 – Benzodiazepine, GABA, and Glutamate Receptors in Cerebral Cortex, Hippocampus, Basal Ganglia, and Cerebellum (1991) (13)
Normal caudate glucose metabolism in persons at risk for Huntington??s disease (1987) (12)
Progressive supranuclear palsy: Postmortem chemical analysis (1985) (12)
Atypical progressive stroke syndrome associated with oral contraceptives and cigarette use. (1987) (11)
Huntington's Disease: Lessons from and for Molecular Neuroscience (1995) (11)
GABA and benzodiazepine receptors in basal ganglia function (1984) (11)
HTRF analysis of soluble huntingtin in PHAROS PBMCs (2013) (10)
Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells. (2006) (10)
Long-term follow-up of percutaneousradiofrequency sacral rhizotomy (1990) (10)
The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study (2019) (10)
Impairment of energy metabolism and excitotoxic cell death in Huntington disease. (1997) (10)
Diagnosis of acute abdominal injuries in patients with spinal shock: value of diagnostic peritoneal lavage. (1980) (10)
In vivo [3H]flunitrazepam binding: imaging of receptor regulation. (1986) (9)
Implantation of brain tumors with Cf-252. Use of computed tomography and magnetic resonance imaging to guide insertion and evaluate response. (1984) (9)
A SENSITIVE SPECIFIC ENZYMATIC‐FLUOROMETRIC ASSAY FOR HOMOCARNOSINE 1 (1973) (9)
Excitatory and inhibitory amino acid binding sites in human dentate nucleus (1991) (9)
Localization of the peripheral-type benzodiazepine binding site to mitochondria of human glioma cells (1992) (9)
Contamination of commercially available quisqualic acid by glutamate-like and aspartate-like substances (1989) (8)
Treatment of Alzheimer's disease. (1992) (8)
Human brain receptor distribution. (1986) (8)
Medulloblastoma: recent advances and directions in diagnosis and management--Part I. (1984) (8)
Massachusetts Alzheimer's Disease Research Center: Progress and challenges (2015) (7)
Head injury and cytochrome P-450 enzymes (1993) (7)
The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers. (2017) (7)
Sex may influence motor phenotype in a novel rodent model of cerebral palsy (2019) (7)
Autoradiographic analysis of L-3H-glutamate receptors in mammalian brain (1986) (7)
Impact of Endoscopic Surgical Techniques on Efficiency in Pituitary Surgery (2011) (7)
Pharmacology of GABA-mediated inhibition of spinal cord neurons in vivo and in primary dissociated cell culture (1981) (7)
Antisense oligodeoxynucleotides directed against mGluR5 glutamate receptor protect against malonic acid lesions in rat striatum (1996) (6)
Common threads in neurodegenerative disorders of aging (2006) (6)
Long-term follow-up of percutaneous radiofrequency sacral rhizotomy. (1990) (6)
Failure of nonprotein calories to mediate protein conservation in brain-injured patients. (1986) (6)
The problem of acute abdominal disease during spinal shock. (1979) (6)
Alban G. Smith and the beginnings of spinal surgery (1987) (6)
GLYCINE RECEPTORS IN THE NERVOUS SYSTEM (1984) (5)
Advanced magnetic resonance imaging and neuropsychological assessment for detecting brain injury in a prospective cohort of university amateur boxers (2017) (5)
Authors' response to commentaries (1989) (5)
Interstitial 252Cf neutron therapy for glioblastoma multiforme* (1982) (5)
Neurobiology of Disease Interactions between Metabotropic Glutamate 5 and Adenosine A 2 A Receptors in Normal and Parkinsonian Mice (2005) (4)
Reply from W.F. Maragos and colleagues (1987) (4)
219 Liquid Biopsy Can Distinguish Recurrent Glioblastomas From Pseudoprogression and Radiation Necrosis After Concurrent Radiochemotherapy. (2016) (4)
A Comparative Study of Laboratory Parameters in Head-Injured Patients Receiving Either Phenytoin or Placebo for 24 Months (1985) (4)
Californium neutron brachytherapy for glioblastoma multiforme (1989) (4)
Selective metabotropic receptor agonists distinguish non-ionotropic glutamate binding sites (1997) (4)
Anxiety and medical diagnostic procedures: Results with patients “at risk” for huntington's disease undergoing pet scan (1991) (4)
The role of mitochondrial DNA in Huntington’s disease (2008) (4)
A template for rigid stereotaxic afterloading brachytherapy of the brain. (1993) (4)
Evidence for reactive synaptogenesis in the ventrolateral thalamus and red nucleus of the rat: changes in high affinity glutamate uptake and numbers of corticofugal fiber terminals (2004) (3)
Glutamate receptor genes in Parkinson's disease. (1996) (3)
Computer-assisted estimates of lesion sizes and shrinkage in denervated areas from receptor autoradiograms using a digitizing tablet (1984) (3)
[Huntington chorea. Animal models reveal new hypotheses for pathophysiology and therapy]. (1999) (3)
Work in progress: /sup 252/Cf neutron brachytherapy for hemispheric malignant glioma. [/sup 60/Co] (1982) (3)
Intraventricular Administration of a Caspase Inhibitor Delays Disease Progression and Mortality in a Mouse Model of Huntington's Disease (1999) (3)
Identification by Electron Microscope Autoradiography (1976) (3)
Immunohistochemical localization of metabotropic glutamate receptors (mGluRs) in the rat basal ganglia (1996) (2)
Synthesis of [18F]phencyclidines for glutamate receptor mapping (1989) (2)
Phenotype–genotype discrepancies in the prospective Huntington at‐risk observational study (2019) (2)
Experience with Cf‐252 Neutron Therapy for Malignant Glioma (1982) (2)
Medulloblastoma: recent advances and directions in diagnosis and management. Part II. (1984) (2)
Striatal Inhomogeneities and Basal (1986) (2)
The treatment and diagnosis of Wilson's disease (1988) (1)
NONAGENARIANS WITH HUNTINGTON DISEASE (HD) HAVE LOW CAG REPEATS (1999) (1)
Sensitive and specific enzymatic assay for homocarnosine (1973) (1)
Metabotropic glutamate receptors modulate striatal quinolinic acid toxicity (1996) (1)
What We Know and What We Have Left to Learn (2001) (1)
Neutron brachytherapy for malignant glioma at the University of Kentucky, Lexington (1986) (1)
CT and MR for brain tumor implant therapy using CF-252 neutrons (2004) (1)
Phenytoin-induced hypotension in animals receiving sympathomimetic pressor support. (1980) (1)
Proper analysis of clinical trials for malignant glioma. (1982) (1)
Synthesis and Receptor Binding Studies of (±)l-Iodo-MK-801 (1989) (1)
Excitatory amino acidergic pathways and receptors in the basal ganglia (1991) (1)
219 Liquid Biopsy Can Distinguish Recurrent Glioblastomas From Pseudoprogression and Radiation Necrosis After Concurrent Radiochemotherapy. (2016) (1)
A malignant glioma therapeutic staging system for Cf-252 neutron brachytherapy at the University of Kentucky (1986) (1)
Classics in neurology. Benjamin Winslow Dudley and the surgical treatment of epilepsy. (1987) (1)
Gamma Knife® radiosurgery: its use and indications in neuro-ophthalmology (1998) (1)
L-glutamate uptake decreases in lumbar and cervical spinal cord of monkey contralateral to sensorimotor ablations (1981) (1)
The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. (2019) (1)
Characteristics of muscarinic acetylcholine receptors in neonatal and adult human brain (1982) (1)
Increased doses of phenytoin for infants. (1978) (1)
Causes Of Alzheimer’s Disease (1996) (0)
Huntington's Disease Homozygotes (1987) (0)
Chapter 32. Alcohol-Related Seizures (2008) (0)
InteractionsbetweenMetabotropicGlutamate5and AdenosineA 2A ReceptorsinNormalandParkinsonianMice (2005) (0)
Effect of Cf-252 neutron implantation on dog brain (1986) (0)
Happing cation channels: Synthesis of [125I] and [18F] analogs of MK‐801 (1989) (0)
Accuracy of NEO-PI-R ratings in the assessment of personality change following traumatic brain injury (1998) (0)
Gene expression changes in corticostriatal neurons of Huntington's Disease transgenic mice and postmortem human brains (2006) (0)
Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
Alcohol‐Related Seizures (2010) (0)
252CF Neutron brachytherapy for malignant glioma at the University of Kentucky and a malignant glioma therapeutic staging system (1986) (0)
Stereotactic radiosurgery (SRS) dose selection for ≤ 2 cm brain metastases: the influence of planned Whole Brain Radiation Therapy (WBRT) (2001) (0)
Reply (1990) (0)
The role of mitochondrial DNA in Huntington's disease (2008) (0)
2085 The prognosting significance of midline shift on survival of patients presenting with glioblastoma multiforme (GBM) (1999) (0)
Receptors in the Basal Ganglia (1989) (0)
Prognostic factors in patients with resected single brain metastases: evaluation of recursive partitioning analysis (RPA) classes I and II (2001) (0)
Excitatory amino acid receptors in the brain : membrane binding and receptor EAA pharmacology j autoradiographic approaches (0)
YOUNG, Anne: Massachusetts/USA (2019) (0)
HUNTINGTONʼS DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY IN AN 80 YEAR-OLD MAN (1996) (0)
High protein enteral feedings: A means of achieving positive nitrogen balance in head-injured patients (1986) (0)
New form of familial Parkinson‐dementia syndrome and progressive supranuclear palsy (1984) (0)
Future directions for research on Alzheimer's disease (1994) (0)
COMPUTER-ASSISTE D ESTIMATES OF LESION SIZES AND SHRINKAGE IN DENERVATED AREAS FROM RECEPTOR (1984) (0)
A New Rodent Model of Dystonic Cerebral Palsy (S35.002) (2018) (0)
144 Chondrosarcoma Radiosurgery: Report of the North American Gamma Knife Consortium (2013) (0)
Biochemistry of Mental Disorders: New Vistas (1978) (0)
Safety and antiemetic effects of metoclopramide in metrizamide myelography. (1987) (0)
Analysis of the Behavioral Features Conferred by the Intermediate Allele for Huntington Disease in the Prospective Huntington at Risk Observational Study (PHAROS) (PL01.003) (2012) (0)
D 1 and d 2 dopamine receptor quantitative autoradiography using tritiated n propylnorapomorphine (1985) (0)
Massachusetts General Hospital honors Anne Young for two decades as chief of neurology service: world-renowned researcher enters the next phase of her career by focusing on mentoring of the next generation. (2013) (0)
Regional specificity of transcriptional changes in early grade Huntington's disease brain (2005) (0)
Editorial Board (1991) (0)
Anatomical And Pharmacological Comparisons Between Dopamine D-1 And D-2 Receptors In Mammalian Cns (1988) (0)
Glutamate Receptors and Glutamate Corticofugal Pathways (1986) (0)
Impact of SRS (stereotactic radiosurgery) dose on survival among 98 patients with 1–3 brain metastases ≤2 cm (2004) (0)
Chorea Huntington: Animal models direct the way to a better pathophysiological understanding and new therapeutical approaches (1999) (0)
QUANTITATIVE A U T O ~ D I O G ~ H Y OF L-I3HIGLUTAMATE BINDING TO RAT BRAIN (2002) (0)
QUANTITATIVE AUTO~DIOG~HY OF L-I3HIGLUTAMATE BINDING TO RAT BRAIN (1983) (0)
D 1 and d 2 dopamine receptor distributions in kitten and monkey striatum (1986) (0)
Editorial Board (2011) (0)
Editorial Board (2007) (0)
REGIONAL ONTOGENY OF A UNIQUE GLUTA~A~ R~COGNI~O~ SITE IN RAT BRAIN: AN AUTORA~IOGRA~H~C (1990) (0)
Neurotransmitters and Receptors in the Basal Ganglia (2019) (0)
Author response for "The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study" (2019) (0)
Inhibitionof caspase-1 slowsdiseaseprogression inamousemodel ofHuntington ’ sdisease (0)
Decline in cortical gamma aminobutyric acid a and gamma aminobutyric acid b sites in alzheimers dementia (1985) (0)
CALIFORNIUM NEUTRON BRACRYTRERAPY FOR GLIOBLASTOMA MULTIFORME (1989) (0)

This paper list is powered by the following services:

Other Resources About Anne B. Young

en.wikipedia.org

What Schools Are Affiliated With Anne B. Young?

Anne B. Young is affiliated with the following schools:

Image Attributions

Image Source for Anne B. Young